The lidocaine, 7%/tetracaine, 7%, cream Pliaglis (Galderma Laboratories, Fort Worth, Texas) (hereinafter, “LT peel”) is a novel topical anesthetic cream that forms a self-occlusive, pliable membrane on exposure to air. The LT peel has been shown to be a safe and effective form of local anesthesia for various dermatologic procedures.1 Minimal adverse effects associated with the LT peel have been reported, limited primarily to transient skin erythema with or without skin discoloration or edema.1 Herein, we report a case of contact urticaria and discuss possible causes of such allergic manifestations and potential hazards and precautions recommended with the use of the LT peel.
Channual J, Wu JJ, Zachary CB. Localized Contact Urticaria Caused by Lidocaine/Tetracaine Peel. Arch Dermatol. 2009;145(4):499–500. doi:10.1001/archdermatol.2009.56
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: